Celecoxib drug study in children on leukemia treatment
Treatments studied
Part of Pain clinical trials.
This trial studies how celecoxib moves through a child’s body and how much reaches the fluid around the brain and spinal cord. It’s for children (age 2–12) who are in the maintenance phase of certain blood cancers, to better understand dosing and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 2 to 12 years
- Be in the maintenance phase of treatment for ALL or lymphoblastic lymphoma, and in remission
- Not have certain blood cancer types like AML
- Have normal kidney and liver blood tests in the last 30 days
- No history of ulcer disease in the stomach or intestines
- No allergy to celecoxib or other anti-inflammatory pain medicines (NSAIDs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This trial studies a new experimental drug called CBX-12 for children, teens, and young adults with solid tumors that have returned or are hard to treat. The drug is designed to target and kill cancer cells, and the study will find the best dose and see how well it works.
This trial tests a treatment plan for children with newly diagnosed acute lymphoblastic leukemia (ALL) that is considered standard-risk. It aims to see if the treatment is effective and safe.
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
Hear when a new Pharmacokinetics of Celecoxib in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.